Helixgate

Helixgate

Uncategorized

Fauci adviser David Morens indicted for concealing emails, avoiding records requests

WASHINGTON — David Morens, a former top National Institute of Allergy and Infectious Diseases official, was indicted Tuesday on allegations that he concealed records from Freedom of Information Act requests. 

Trump administration officials said in a legal filing that Morens hid and falsified records to undermine debate about the origins of the virus that spurred the Covid-19 pandemic — and received kickbacks for doing so, including wine and offers of future meals at high-end restaurants. Morens was a senior adviser to former NIAID Director Anthony Fauci, who is not named directly in the indictment. 

Read the rest…

Read More

Published

on

WASHINGTON — David Morens, a former top National Institute of Allergy and Infectious Diseases official, was indicted Tuesday on allegations that he concealed records from Freedom of Information Act requests. 

Trump administration officials said in a legal filing that Morens hid and falsified records to undermine debate about the origins of the virus that spurred the Covid-19 pandemic — and received kickbacks for doing so, including wine and offers of future meals at high-end restaurants. Morens was a senior adviser to former NIAID Director Anthony Fauci, who is not named directly in the indictment. 

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Viridian data lift prospects for thyroid eye disease drug

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

Read More

Published

on

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

Read More

Continue Reading

Uncategorized

Pfizer is a 2029 story but Q126 lays foundation for growth

Published

on

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

Continue Reading

Uncategorized

Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech’s $83M

Published

on

A blood test might predict who will respond to Wegovy; Viridian’s thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets.

🧬 Second life for a gene therapy: A Cleveland-based biotech called …

Continue Reading
Advertisement

Trending